hby-097 and Acquired-Immunodeficiency-Syndrome

Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiviral Agents; Cohort Studies; Double-Blind Method; Drug Combinations; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Mutation; Placebos; Quinoxalines; Reverse Transcriptase Inhibitors; Viral Load; Viremia; Virus Replication

A three-month human trial will be conducted in Los Angeles, New York, and San Francisco, to test a new drug, HBY 097. In laboratory tests, HBY 097 has weakened HIV. Volunteers will begin a regimen of either HBY 097, AZT, or the combination. The study will measure all mutations that develop in the HIV reverse transcriptase enzyme. Participants must have a CD4 count between 200 and 500, and have not received any approved HIV treatment before.

Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV; HIV Reverse Transcriptase; Humans; Los Angeles; Mutation; New York; Quinoxalines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; San Francisco

Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials, Phase I as Topic; HIV Reverse Transcriptase; Humans; Quinoxalines; Reverse Transcriptase Inhibitors